151 related articles for article (PubMed ID: 38358343)
21. Emerging Insights on the Diverse Roles of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Chronic Liver Diseases: Cholesterol Metabolism and Beyond.
Grewal T; Buechler C
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35162992
[TBL] [Abstract][Full Text] [Related]
22. Diverse Effects of Cilostazol on Proprotein Convertase Subtilisin/Kexin Type 9 between Obesity and Non-Obesity.
Chen PW; Tseng SY; Chang HY; Lee CH; Chao TH
Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077166
[TBL] [Abstract][Full Text] [Related]
23. Small-interfering RNA targeting proprotein convertase subtilisin/kexin type 9 might promote fatty liver disease and hepatocellular carcinoma through upregulation of CD36.
Fan FS
Tumour Biol; 2023; 45(1):73-80. PubMed ID: 37694331
[TBL] [Abstract][Full Text] [Related]
24. Dose-dependent effects of siRNA-mediated inhibition of SCAP on PCSK9, LDLR, and plasma lipids in mouse and rhesus monkey.
Jensen KK; Tadin-Strapps M; Wang SP; Hubert J; Kan Y; Ma Y; McLaren DG; Previs SF; Herath KB; Mahsut A; Liaw A; Wang S; Stout SJ; Keohan C; Forrest G; Coelho D; Yendluri S; Williams S; Koser M; Bartz S; Akinsanya KO; Pinto S
J Lipid Res; 2016 Dec; 57(12):2150-2162. PubMed ID: 27707816
[TBL] [Abstract][Full Text] [Related]
25. Proprotein convertase subtilisin kexin type 9 promotes intestinal overproduction of triglyceride-rich apolipoprotein B lipoproteins through both low-density lipoprotein receptor-dependent and -independent mechanisms.
Rashid S; Tavori H; Brown PE; Linton MF; He J; Giunzioni I; Fazio S
Circulation; 2014 Jul; 130(5):431-41. PubMed ID: 25070550
[TBL] [Abstract][Full Text] [Related]
26. Proprotein Convertase Subtilisin/Kexin Type 9 Loss-of-Function Is Detrimental to the Juvenile Host With Septic Shock.
Atreya MR; Whitacre BE; Cvijanovich NZ; Bigham MT; Thomas NJ; Schwarz AJ; Weiss SL; Fitzgerald JC; Allen GL; Lutfi R; Nowak JE; Quasney MW; Shah AS; Wong HR
Crit Care Med; 2020 Oct; 48(10):1513-1520. PubMed ID: 32769621
[TBL] [Abstract][Full Text] [Related]
27.
Lebeau PF; Byun JH; Platko K; Al-Hashimi AA; Lhoták Š; MacDonald ME; Mejia-Benitez A; Prat A; Igdoura SA; Trigatti B; Maclean KN; Seidah NG; Austin RC
JHEP Rep; 2019 Dec; 1(6):418-429. PubMed ID: 32039393
[TBL] [Abstract][Full Text] [Related]
28. Pcsk9 Deletion Promotes Murine Nonalcoholic Steatohepatitis and Hepatic Carcinogenesis: Role of Cholesterol.
Ioannou GN; Lee SP; Linsley PS; Gersuk V; Yeh MM; Chen YY; Peng YJ; Dutta M; Mascarinas G; Molla B; Cui JY; Savard C
Hepatol Commun; 2022 Apr; 6(4):780-794. PubMed ID: 34816633
[TBL] [Abstract][Full Text] [Related]
29. Proprotein convertase subtilisin/kexin type 9 (PCSK9) affects gene expression pathways beyond cholesterol metabolism in liver cells.
Lan H; Pang L; Smith MM; Levitan D; Ding W; Liu L; Shan L; Shah VV; Laverty M; Arreaza G; Zhang Q; Murgolo NJ; Hernandez M; Greene JR; Gustafson EL; Bayne ML; Davis HR; Hedrick JA
J Cell Physiol; 2010 Jul; 224(1):273-81. PubMed ID: 20333646
[TBL] [Abstract][Full Text] [Related]
30. Nutritional and Lipid Modulation of PCSK9: Effects on Cardiometabolic Risk Factors.
Krysa JA; Ooi TC; Proctor SD; Vine DF
J Nutr; 2017 Apr; 147(4):473-481. PubMed ID: 28179493
[TBL] [Abstract][Full Text] [Related]
31. Resveratrol downregulates PCSK9 expression and attenuates steatosis through estrogen receptor α-mediated pathway in L02 cells.
Jing Y; Hu T; Lin C; Xiong Q; Liu F; Yuan J; Zhao X; Wang R
Eur J Pharmacol; 2019 Jul; 855():216-226. PubMed ID: 31085239
[TBL] [Abstract][Full Text] [Related]
32. Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration.
Zaid A; Roubtsova A; Essalmani R; Marcinkiewicz J; Chamberland A; Hamelin J; Tremblay M; Jacques H; Jin W; Davignon J; Seidah NG; Prat A
Hepatology; 2008 Aug; 48(2):646-54. PubMed ID: 18666258
[TBL] [Abstract][Full Text] [Related]
33. Tetrahydropalmatine ameliorates hepatic steatosis in nonalcoholic fatty liver disease by switching lipid metabolism via AMPK-SREBP-1c-Sirt1 signaling axis.
Yin X; Liu Z; Wang J
Phytomedicine; 2023 Oct; 119():155005. PubMed ID: 37562090
[TBL] [Abstract][Full Text] [Related]
34. Role of PCSK9 in lipid metabolic disorders and ovarian dysfunction in polycystic ovary syndrome.
Wang M; Zhao D; Xu L; Guo W; Nie L; Lei Y; Long Y; Liu M; Wang Y; Zhang X; Zhang L; Li H; Zhang J; Yuan D; Yue L
Metabolism; 2019 May; 94():47-58. PubMed ID: 30768966
[TBL] [Abstract][Full Text] [Related]
35. The Role of Proprotein Convertase Subtilisin/Kexin Type 9 in Nephrotic Syndrome-Associated Hypercholesterolemia.
Haas ME; Levenson AE; Sun X; Liao WH; Rutkowski JM; de Ferranti SD; Schumacher VA; Scherer PE; Salant DJ; Biddinger SB
Circulation; 2016 Jul; 134(1):61-72. PubMed ID: 27358438
[TBL] [Abstract][Full Text] [Related]
36. Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9.
Jang HD; Lee SE; Yang J; Lee HC; Shin D; Lee H; Lee J; Jin S; Kim S; Lee SJ; You J; Park HW; Nam KY; Lee SH; Park SW; Kim JS; Kim SY; Kwon YW; Kwak SH; Yang HM; Kim HS
Eur Heart J; 2020 Jan; 41(2):239-252. PubMed ID: 31419281
[TBL] [Abstract][Full Text] [Related]
37. Hepatic Glucagon Signaling Regulates PCSK9 and Low-Density Lipoprotein Cholesterol.
Spolitu S; Okamoto H; Dai W; Zadroga JA; Wittchen ES; Gromada J; Ozcan L
Circ Res; 2019 Jan; 124(1):38-51. PubMed ID: 30582457
[TBL] [Abstract][Full Text] [Related]
38. Chitosan oligosaccharides enhance lipid droplets via down-regulation of PCSK9 gene expression in HepG2 cells.
Yang X; Zhang J; Chen L; Wu Q; Yu C
Exp Cell Res; 2018 May; 366(2):152-160. PubMed ID: 29548750
[TBL] [Abstract][Full Text] [Related]
39. FoxO3 transcription factor and Sirt6 deacetylase regulate low density lipoprotein (LDL)-cholesterol homeostasis via control of the proprotein convertase subtilisin/kexin type 9 (Pcsk9) gene expression.
Tao R; Xiong X; DePinho RA; Deng CX; Dong XC
J Biol Chem; 2013 Oct; 288(41):29252-9. PubMed ID: 23974119
[TBL] [Abstract][Full Text] [Related]
40. Peroxisome Proliferator-activated receptor γ activation by ligands and dephosphorylation induces proprotein convertase subtilisin kexin type 9 and low density lipoprotein receptor expression.
Duan Y; Chen Y; Hu W; Li X; Yang X; Zhou X; Yin Z; Kong D; Yao Z; Hajjar DP; Liu L; Liu Q; Han J
J Biol Chem; 2012 Jul; 287(28):23667-77. PubMed ID: 22593575
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
